Similarly, the KEYFORM-007 study, which investigated the efficacy of pembrolizumab + anti-LAG-3 antibody favezelimab combination therapy as late-line chemotherapy for PD-L1-positive MSS colon cancer, did not show a significant improvement in OS, its primary endpoint [64]. This evidence concerns the gene LAG3 and malignant colon neoplasm.